Heroin Dependence Clinical Trial
Official title:
Buprenorphine/Naloxone Versus Clonidine For Out-patient Opiate Detoxification
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.
Patients randomized to the BUP/NX arm will receive daily doses for 13 days with sublingual administration of 2 mg buprenorphine/0.5 mg naloxone tablet(s) and/or an 8 mg buprenorphine/2.0 mg naloxone tablet(s). The starting dose on day 1 is 4 mg/1 mg BUP/NX with an additional 4 mg/1 mg, if needed, escalating in a step-wise manner to 16 mg/4 mg BUP/NX on day 3 and tapering to 2 mg/ 0.5 mg BUP/NX by days 12 to 13. Patients randomized to the clonidine arm will receive oral clonidine (0.05 to 0.1 mg depending upon weight) every 4 to 6 hours for 24 hours not to exceed 0.6 mg total on day 1. On day 2, a clonidine transdermal patch will be applied (0.1 mg/day/7-day patch with number of patches adjusted by weight). Oral clonidine will continue to be given on the second day of detoxification and increased to 0.2 mg every 6 hours or 0.1 mg every 3 hours not to exceed 0.8 mg over 24 hours. Patches will be worn all 13 days of detoxification. The dose of clonidine will be adjusted according to the proposed detoxification schedule, patient's weight, tolerance, and systolic blood pressure. Patients will receive counseling according to procedures in existence at each CTP throughout the study. Self-help detoxification handbooks will be distributed to all study participants. ;
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00577408 -
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
|
Phase 3 | |
| Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
| Completed |
NCT00000210 -
Treatment Efficacy for Drug Abuse and AIDS Prevention - 1
|
Phase 2 | |
| Completed |
NCT00000211 -
Treatment Efficacy for Drug Abuse and AIDS Prevention - 2
|
Phase 2 | |
| Completed |
NCT02324725 -
Biomarkers of Injectable Extended Release Naltrexone Treatment
|
Phase 4 | |
| Withdrawn |
NCT00000330 -
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
|
Phase 2 | |
| Completed |
NCT00249457 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2
|
N/A | |
| Completed |
NCT00218127 -
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
|
Phase 2 | |
| Completed |
NCT04133974 -
Methadone Induced Memory Retrieval-extinction Procedure in Heroin Addicts
|
N/A | |
| Completed |
NCT00015288 -
Buprenorphine and Naloxone Combination Study - 10
|
Phase 1 | |
| Terminated |
NCT03711318 -
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
|
Phase 3 | |
| Recruiting |
NCT02541526 -
Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia
|
Phase 3 | |
| Active, not recruiting |
NCT02541513 -
An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence
|
Phase 3 | |
| Completed |
NCT01760473 -
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
|
Phase 3 | |
| Terminated |
NCT01395797 -
Pioglitazone for Heroin and for Nicotine Dependence
|
Phase 1/Phase 2 | |
| Completed |
NCT01668706 -
Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts
|
N/A | |
| Active, not recruiting |
NCT00609089 -
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
|
Phase 1/Phase 2 | |
| Completed |
NCT00684840 -
Effects of Stress and Other Factors on Opiate Drug Choice.
|
N/A | |
| Completed |
NCT00759005 -
Effect of Stress on Heroin-Related Memory Retrieval
|
N/A | |
| Completed |
NCT00218530 -
Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1
|
Phase 1 |